检索结果-南通市图书馆

Analysis of long noncoding RNA-associated competing endogenous RNA network in glucagon-like peptide-1 receptor agonist-mediated protection inβcells

引用

World Journal of Diabetes 2020年第9期11卷 374-390页

作者： Li-Juan Cui Tao Bai Lin-Ping Zhi Zhi-Hong Liu Tao Liu Huan Xue Huan-Huan Yang Xiao-Hua Yang Min Zhang Ya-Ru Niu Yun-Feng Liu Yi Zhang Department of Pharmacology Basic Medical CollegeShanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina Department of Endocrinology The First Clinical Hospital of Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina Department of Respiratory Medicine The First Clinical Hospital of Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina Department of General Surgery Shanxi Bethune HospitalTaiyuan 030006Shanxi ProvinceChina College of Pharmacy Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina Second Clinical Medical College Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina

BACKGROUND Long noncoding RNAs(lncRNAs)and mRNAs are widely involved in various physiological and pathological *** use of glucagon-like peptide-1 receptor agonists(GLP-1RAs)is a novel therapeutic strategy that could promote insulin secretion and decrease the rate ofβ-cell apoptosis in type 2 diabetes mellitus(T2DM)***,the specific lncRNAs and mRNAs and their functions in these processes have not been fully identified and *** To identify the lncRNAs and mRNAs that are involved in the protective effect of GLP-1RA inβcells,and their *** Rat gene microarray was used to screen differentially expressed(DE)lncRNAs and mRNAs inβcells treated with geniposide,a *** Ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway enrichment analyses were performed to assess the underlying functions of DE *** mRNAs were filtered using the STRING database and the Cytoscape plugin,*** order to reveal the regulatory relationship between lncRNAs and hub mRNAs,their co-expression network was constructed based on the Pearson coefficient of DE lncRNAs and mRNAs,and competing endogenous RNA(ceRNA)mechanism was explored through miRanda and TargetScan *** We identified 308 DE lncRNAs and 128 DE mRNAs with a fold change filter of≥1.5 and P valuereceptor signaling pathway,inflammatory response,calcium signaling pathway,positive regulation of cell proliferation,and ERK1 and ERK2 ***,Htr2a,and Agtr1a were screened as hub mRNAs using the STRING database and the Cytoscape plugin,*** result was further verified using SwissTargetPrediction *** the co-expression network and competing endogenous(ceRNA)mechanism,we identified seven lncRNAs(NONRATT027738,NONRATT027888,NONRATT030038,etc.)co-expressed with the three hub mRNAs(Pomc,Htr2a,and Agtr1a)based on the Pearson coefficient of

关键词： Type 2 diabetes βcell Long noncoding RNA Competing endogenous RNA Co-expression analysis glucagon-like peptide-1 receptor agonist

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Advancements in glucagon-like peptide-1 receptor agonist therapy for type 2 diabetes

引用

Journal of Chinese Pharmaceutical Sciences 2024年第8期33卷 667-685页

作者： Yaping Peng Ying Fu Capital Medical University Beijing100069China Center for Endocrine Metabolism and Immune Diseases Beijing Luhe HospitalCapital Medical UniversityBeijing 101149China Beijing Key Laboratory of Diabetes Research and Care Beijing 101149China

glucagon-like peptide-1 receptor agonists(GLP-1RAs)are novel hypoglycemic agents that have garnered widespread acceptance in the treatment of type 2 diabetes,largely attributed to their safety profile,potent hypoglycemic effects,and metabolic *** primary mechanisms of action encompass promoting insulin release,inhibiting glucagon secretion,bolstering pancreatic islet cell function,curbing appetite,and slowing gastric *** article delves into the clinical evidence underscoring the efficacy of various ***,these agents have demonstrated marked improvements in glycemic control,significant weight reduction,and substantial cardiovascular and renal ***,certain adverse effects of GLP-1RAs,such as pancreatitis and intestinal obstruction,have been reported,warranting vigilant monitoring by healthcare *** sum,GLP-1RAs hold significant promise in the management of type 2 diabetes,offering notable cardiovascular and renal advantages.

关键词： glucagon-like peptide-1 receptor agonist Type 2 diabetes Metabolic diseases

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Practical guide:glucagon-like peptide-1 and dual glucosedependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus

引用

World Journal of Diabetes 2024年第3期15卷 331-347页

作者： Saleh Fahad Alqifari Omar Alkomi Abdullah Esmail Khadijeh Alkhawami Shahd Yousri Mohamad Ayham Muqresh Nawwarah Alharbi Abdullah A Khojah Ahmed Aljabri Abdulrahman Allahham Kousalya Prabahar Hanan Alshareef Mohammed Aldhaeefi Tariq Alrasheed Ali Alrabiah Laila A AlBishi Department of Pharmacy Practice Faculty of PharmacyUniversity of TabukTabuk 71491Saudi Arabia Department of Clinical Sciences Sulaiman Alrajhi University-College of MedicineAl Bukayriyah 52726Saudi Arabia Department of Family Medicine Dr.Soliman Fakeeh Hospital DSFHJeddah 21461Saudi Arabia Department of Pharmacy Practice Faculty of PharmacyKing Abdulaziz UniversityJeddah 22252Saudi Arabia Clinical and Administrative Pharmacy Sciences College of PharmacyHoward UniversityWashingtonDC 20059United States Department of Internal Medicine Faculty of MedicineUniversity of TabukTabuk 71491Saudi Arabia Department of Pharmacy Practice Raabe College of PharmacyOhio Northern UniversityOhioOH 45810United States Department of Pediatric Faculty of MedicineUniversity of TabukTabuk 71491Saudi Arabia

Practical guide:glucagon-like peptide-1 and dual glucosedependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus common second-line choice after metformin for treating *** considerations can make selecting and switching between different GLP-1 RAs *** study aims to provide a comprehensive guide for the usage of GLP-1 RAs and dual GIP and GLP-1 RAs for the management of T2DM.

关键词： glucagon-like peptide-1 receptor agonist Diabetes mellitus Metabolic syndrome Dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist Clinical practice Endocrinology

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Exendin-4 attenuates atherosclerosis progression via controlling hematopoietic stem/progenitor cell proliferation

引用

Journal of Molecular Cell Biology 2023年第2期15卷 43-57页

作者： Cen Yan Xiaojuan Ma Sin Man Lam Yuejie Zhang Yu Cao Yuan Dong Li Su Guanghou Shui Yingmei Feng Department of Science and Development Beĳing Youan hospitalCapital Medical UniversityBeĳing 100069China Center of Basic Medical Research Institute of Medical Innovation and ResearchPeking University Third HospitalBeĳing 100191China State Key Laboratory of Molecular Developmental Biology Institute of Genetics and Developmental BiologyChinese Academy of SciencesBeĳing 100101China Neuroscience Research Institute Peking University Center of Medical and Health AnalysisPeking UniversityBeĳing 100191China

Beyond glycemic control, applications of glucagon-like peptide-1 receptor (GLP-1r) agonists (GLP-1 RAs) inhibit inflammationand plaque development in murine atherosclerotic models. However, whether they modulate hematopoietic stem/progenitor cells(HSPCs)to prohibit skewed myelopoiesis in hypercholesteremia remains unknown. In this study, GLP-1r expression in fluorescenceactivated cell sorting (FACS)-sorted wild-type HSPCs was determined by capillary western blotting. Bone marrow cells (BMCs)of wild-type or GLP-1r−/− mice were transplanted into lethally irradiated low-density lipoprotein receptor deficient (LDLr−/−)recipients followed by high-fat diet (HFD) for chimerism analysis by FACS. In parallel, LDLr−/− mice were placed on HFD for 6weeks and then treated with saline or Exendin-4 (Ex-4) for another 6 weeks. HSPC frequency and cell cycle were analyzed byFACS, and intracellular metabolite levels were assessed by targeted metabolomics. The results demonstrated that HSPCs expressedGLP-1r and transplantation of GLP-1r−/− BMCs resulted in skewed myelopoiesis in hypercholesterolemic LDLr−/− *** vitro, Ex-4 treatment of FACS-purified HSPCs suppressed cell expansion and granulocyte production induced by LDL. In vivo, Ex-4treatment inhibited plaque progression, suppressed HSPC proliferation, and modified glycolytic and lipid metabolism in HSPCs ofhypercholesteremic LDLr−/− mice. In conclusion, Ex-4 could directly inhibit HSPC proliferation induced by hypercholesteremia.

关键词： glucagon-like peptide-1 receptor agonist hematopoietic stem/progenitor cells proliferation metabolomics atherosclerosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Exendin-4 and linagliptin attenuate neuroinflammation in a mouse model of Parkinson's disease

引用

Neural Regeneration Research 2023年第8期18卷 1818-1826页

作者： Hai-Yang Yu Tong Sun Zhen Wang Hong Li Duo Xu Jing An Lu-Lu Wen Jia-Yi Li Wen Li Juan Feng Department of Neurology Shengjing Hospital of China Medical UniversityShenyangLiaoning ProvinceChina Department of Pediatrics Shengjing Hospital of China Medical UniversityShenyangLiaoning ProvinceChina Laboratory of Research in Parkinson’s Disease and Related Disorders Health Sciences InstituteChina Medical UniversityShenyangLiaoning ProvinceChina Neural Plasticity and Repair Unit Department of Experimental Medical ScienceLund UniversityLundSweden

Use of glucagon-like peptide-1 receptor agonist or dipeptidyl peptidase 4 inhibitor has been shown to lower the incidence of Parkinson's disease in patients with diabetes ***,using these two treatments may help treat Parkinson's *** further investigate the mechanisms of action of these two compounds,we established a model of Parkinson's disease by treating mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and then subcutaneously injected them with the glucagon-like peptide-1 receptor agonist exendin-4 or the dipeptidyl peptidase 4 inhibitor *** found that both exendin-4 and linagliptin reversed motor dysfunction,glial activation,and dopaminergic neuronal death in this *** addition,both exendin-4 and linagliptin induced microglial polarization to the anti-inflammatory M2 phenotype and reduced pro-inflammatory cytokine ***,in vitro experiments showed that treatment with exendin-4 and linagliptin inhibited activation of the nucleotide-binding oligomerization domain-and leucine-rich-repeat-and pyrin-domaincontaining 3/caspase-1/interleukin-1βpathway and subsequent pyroptosis by decreasing the production of reactive oxygen *** findings suggest that exendin-4 and linagliptin exert neuroprotective effects by attenuating neuroinflammation through regulation of microglial polarization and the nucleotidebinding oligomerization domain-and leucine-rich-repeat-and pyrin-domain-containing 3/caspase-1/interleukin-1βpathway in a mouse model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,***,these two drugs may serve as novel anti-inflammatory treatments for Parkinson's disease.

关键词： diabetes mellitus dipeptidyl peptidase 4 inhibitor exendin-4 glucagon-like peptide-1 receptor agonist 1-methyl-4-phenyl-1 2 3 6-tetrahydropyridine linagliptin microglia neuroinflammation NLRP3 inflammasome Parkinson's disease pyroptosis

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Novel glucose-lowering drugs for non-alcoholic fatty liver disease

引用

World Journal of Diabetes 2021年第1期12卷 84-97页

作者： Zuo-Di Fu Xiao-Ling Cai Wen-Jia Yang Ming-Ming Zhao Ran Li Yu-Feng Li Department of Endocrinology Beijing Friendship Hospital Pinggu CampusBeijing 101200China Department of Endocrinology and Metabolism Peking University People’s HospitalBeijing 100044China The Institute of Cardiovascular Sciences School of Basic Medical SciencesHealth Science CenterPeking UniversityBeijing 100079China Sport Science School Beijing Sport UniversityBeijing 100078China Department of Endocrinology Beijing Friendship Hospital Pinggu CampusCapital Medical UniversityBeijing 101200China

BACKGROUND The efficacy of novel glucose-lowering drugs in treating non-alcoholic fatty liver disease(NAFLD)is *** To evaluate the efficacy of glucose-lowering drugs dipeptidyl peptidase-4(DPP-4)inhibitors,glucagon-like peptide-1 receptor agonists(GLP-1 RAs),and sodiumglucose cotransporter 2(SGLT2)inhibitors in treating NAFLD and to perform a comparison between these *** Electronic databases were systematically *** inclusion criteria were:Randomized controlled trials comparing DPP-4 inhibitors,GLP-1 RAs,or SGLT2 inhibitors against placebo or other active glucose-lowering drugs in NAFLD patients,with outcomes of changes in liver enzyme[alanine aminotransferase(ALT)and/or aspartate aminotransferase(AST)]from *** Nineteen studies were finally included in this *** with placebo or other active glucose-lowering drug treatment,treatment with DPP-4 inhibitors,GLP-1 RAs,and SGLT2 inhibitors all led to a significant decrease in ALT change and AST change from *** difference between the DPP-4 inhibitor and SGLT2 inhibitor groups in ALT change was significant in favor of DPP-4 inhibitor treatment(P1 RAs,and SGLT2 inhibitors resulted in improvements in serum ALT and AST levels and body fat composition,indicating a beneficial effect in improving liver injury and reducing liver fat in NAFLD patients.

关键词： Non-alcoholic fatty liver disease Glucose-lowering drug Meta-analysis Dipeptidyl peptidase-4 inhibitor Sodium-glucose cotransporter 2 inhibitor glucagon-like peptide-1 receptor agonist

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Incretin based therapy and pancreatic cancer:Realising the reality

引用

World Journal of Gastroenterology 2022年第25期28卷 2881-2889页

作者： Varun Suryadevara Ayan Roy Jayaprakash Sahoo Sadishkumar Kamalanathan Dukhabandhu Naik Pazhanivel Mohan Raja Kalayarasan Department of Endocrinology Jawaharlal Institute of Postgraduate Medical Education and ResearchPuducherry 605006India Department of Endocrinology All India Institute of Medical SciencesKalyani 741245West BengalIndia Department of Medical Gastroenterology Jawaharlal Institute of Postgraduate Medical Education and ResearchPuducherry 605006India Department of Surgical Gastroenterology Jawaharlal Institute of Postgraduate Medical Education and ResearchPuducherry 605006India

Incretin-based therapies like glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help maintain the glycaemic control in patients with type 2 diabetes mellitus with additional systemic benefits and little risk of *** medications are associated with low-grade chronic pancreatitis in animal models *** incidence of acute pancreatitis was also reported in some human *** inflammation provides fertile ground for developing pancreatic carcinoma(PC).Although the data from clinical trials and population-based studies have established safety regarding PC,the pathophysiological possibility that low-grade chronic pancreatitis leads to PC *** review the existing literature and describe the relationship between incretin-based therapies and PC.

关键词： Diabetes mellitus Dipeptidyl peptidase-4 inhibitor glucagon-like peptide-1 receptor agonist Incretin Pancreatitis Pancreatic Cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes:A systematic review with multiple network meta-regressions

引用

World Journal of Diabetes 2024年第10期15卷 2135-2146页

作者： Jing-Jing Zhu John P H Wilding Xiao-Song Gu Department of Endocrinology and Metabolic Medicine The Second Affiliated Hospital of Soochow UniversitySuzhou 215004Jiangsu ProvinceChina Department of Cardiovascular and Metabolic Medicine University of LiverpoolLiverpool L697ZXUnited Kingdom Clinical Sciences Centre Liverpool University Hospitals NHS Foundation TrustLiverpool L97ALUnited Kingdom Department of Cardiovascular Medicine The Second Affiliated Hospital of Soochow UniversitySuzhou 215004Jiangsu ProvinceChina

BACKGROUND glucagon-like peptide-1 receptor agonists(GLP-1RA)and sodium-glucose co-transporter-2 inhibitors(SGLT-2I)are associated with significant cardiovascular benefit in type 2 diabetes(T2D).However,GLP-1RA or SGLT-2I alone may not improve some cardiovascular outcomes in patients with prior cardiovascular *** To explore whether combining GLP-1RA and SGLT-2I can achieve additional benefit in preventing cardiovascular diseases in *** The systematic review was conducted according to PRISMA *** protocol was registered on PROSPERO(ID:42022385007).A total of 107049 participants from eligible cardiovascular outcomes trials of GLP-1RA and SGLT-2I were included in network meta-regressions to estimate cardiovascular benefit of the combination *** modification of prior myocardial infarction(MI)and heart failure(HF)was also explored to provide clinical insight as to when the INTRODUCTION The macro-and micro-vascular benefits of glucagon-like peptide-1 receptor agonists(GLP-1RA)and sodium-glucose co-transporter-2 inhibitors(SGLT-2I)are independent of their glucose-lowering effects[1].In patients with type 2 diabetes(T2D),the major cardiovascular outcome trials(CVOT)showed that dipeptidyl peptidase-4 inhibitors(DPP-4I)did not improve cardiovascular outcomes[2],whereas cardiovascular benefit of GLP-1RA or SGLT-2I was significant[3,4].Further subgroup analyses indicated that the background cardiovascular risk should be considered when examining the cardiovascular outcomes of these newer glucose-lowering *** instance,prevention of major adverse cardiovascular events(MACE)was only seen in those patients with baseline atherosclerotic cardiovascular disease[3,4].Moreover,a series of CVOT conducted in patients with heart failure(HF)have demonstrated that(compared with placebo)SGLT-2I significantly reduced risk of hospitalization for HF or cardiovascular death,irrespective of their history of T2D[5-8].However,similar car

关键词： Type 2 diabetes glucagon-like peptide-1 receptor agonist Sodium-glucose co-transporter-2 inhibitor Combination treatment Cardiovascular outcome Systematic review Network meta-regression

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Surgical or medical treatment of obesity-associated type 2 diabetesan increasing clinical conundrum

引用

World Journal of Diabetes 2024年第10期15卷 2036-2040页

作者： Ryan J Jalleh Karen L Jones Md Shahidul Islam Lu Cai Michael Horowitz Adelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health University of Adelaide Endocrine and Metabolic Unit Royal Adelaide HospitalAdelaide 5000South AustraliaAustralia Department of Biochemistry School of Life SciencesUniversity of KwaZulu-NatalDurban 4000KwaZulu-NatalSouth Africa Pediatric Research Institute Departments of PediatricsRadiation OncologyPharmacology and ToxicologyUniversity of LouisvilleWendy Novak Diabetes InstituteNorton Children’s HospitalLouisvilleKY 40202United States

In this editorial,we comment on the article by He et al,specifically in relation to the efficacy of bariatric surgery vs glucagon-like peptide-1 receptor agonist(GLP-1RA)therapy in the management of type 2 diabetes(T2D)associated with *** surgery has now also been shown to be safe and effective in pre-teens and teenagers with obesity and T2D,but information on newer GLP-1RAs in these groups is predictably *** older individuals(age>65 years),both bariatric surgery and GLP-1RA therapy improve cardiovascular ***-tric surgery is not infrequently associated with post-operative postprandial hypoglycemia,which is not the case with GLP-1RAs and,paradoxically,there is evidence that GLP-1RAs may reduce both the frequency and severity of postprandial *** trials of the long-term efficacy of bariatric surgery and GLP-1RAs are indicated.

关键词： glucagon-like peptide-1 glucagon-like peptide-1 receptor agonist Obesity Diabetes Weight loss Bariatric surgery Metabolic surgery Hypoglycemia

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cystic fibrosis-related diabetes:The unmet need

引用

World Journal of Diabetes 2020年第6期11卷 213-217页

作者： Leonardo Pozo Fatimah Bello Yamely Mendez Salim Surani Internal Medicine University of Texas Rio Grande ValleyEdinburgTX 78539United States Research Department Baylor College of MedicineHoustonTexas.77030United States Medical Critical Care Services Corpus Christi Medical CenterCorpus ChristiTX 78404United States

Cystic fibrosis(CF)is a common autosomal recessive *** expectancy of patients with CF continues to improve mainly driven by the evolving therapies for CF-related organ *** prevalence of CF-related diabetes(CFRD)increases exponentially as patients’*** care guidelines for CFRD from 2010,recommend insulin as the mainstay of *** patients with CFRD may not require exogenous insulin due to the heterogeneity of this clinical *** of euglycemia by enhancing endogenous insulin production,secretion and degradation with novel pharmacological therapies like glucagonlike peptide-1 agonist is an option that remains to be fully *** such,the scope of this article will focus on our perspective of glucagon-like peptide-1 receptor agonist in the context of *** potential options such as sodiumglucose cotransporter-2 and dipeptidyl peptidase 4 inhibitors and their impact on this patient population is limited and further studies are required.

关键词： Cystic fibrosis Cystic fibrosis-related diabetes Cystic fibrosis transmembrane conductance regulator Gastric inhibitory polypeptide glucagon-like peptide 1 glucagon-like peptide-1 receptor agonist Dipeptidyl peptidase 4 inhibitors

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：